立体定向消融放疗联合手术治疗早期非小细胞肺癌的整合评估:一项2期临床试验
这项2期单臂试验在可手术的早期非小细胞肺癌患者中评估新辅助立体定向消融放疗(SABR)后手术的病理完全缓解率及肿瘤学和毒性结局。35例可评估患者中病理完全缓解率为60%(95%CI,44%-76%),低于研究假设;30天和90天术后死亡率均为0%,3或4级毒性反应发生于7例患者(18%)。作者认为需进一步研究比较该联合方案与单纯手术切除。
要点
- 新辅助SABR后手术的病理完全缓解率为60%(95%CI,44%-76%),低于研究假设。
- 35例接受手术者可评估,30天和90天术后死亡率均为0%,3或4级毒性反应7例(18%)。
- 接受手术者2年总生存77%(95%CI,48%-91%),局部控制100%(95%CI未定义),区域控制53%(95%CI,22%-76%),远处控制76%(95%CI,45%-91%)。
核心结论
- 早期非小细胞肺癌SABR后病理完全缓解率为60%,低于研究假设。
- 该联合方案的毒性反应与单纯手术系列相当,且无围手术期死亡。
- 作者认为需进一步研究比较该联合方案与单纯手术切除。
研究设计与样本
- 2期单臂试验,2014年9月30日至2017年8月15日入组,中位随访19个月,在一家三级学术癌症中心进行。
- 纳入18岁及以上、T1T2N0M0非小细胞肺癌、体能状态良好且肺储备足以接受手术切除的患者。
- 患者接受风险 адаптированное 分次方案的新辅助SABR,10周后接受手术;共40例患者入组(平均[SD]年龄68[8]岁;23例[58%]女性),其中35例接受手术并可评估主要终点。
主要发现
- 病理完全缓解率(苏木精-伊红染色判定)为60%(95%CI,44%-76%)。
- 30天和90天术后死亡率均为0%;3或4级毒性反应发生于7例患者(18%)。
- 接受手术者2年总生存为77%(95%CI,48%-91%),局部控制为100%(95%CI未定义),区域控制为53%(95%CI,22%-76%),远处控制为76%(95%CI,45%-91%)。
- 治疗后生活质量未下降,随访第一年内癌症治疗功能评估-肺试验结局指数平均评分无显著变化。
局限性
- 病理完全缓解率低于研究假设。
- 作者认为需进一步研究比较该联合方案与单纯手术切除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Stereotactic ablative radiotherapy (SABR) is a standard treatment option in patients with medically inoperable early-stage non-small cell lung cancer (NSCLC), yet the pathologic complete response (pCR) rate after SABR is unknown. Neoadjuvant SABR in patients with cancer who are fit for resection has been hypothesized to improve local control and induce antitumor immune activity, potentially leading to better outcomes. OBJECTIVES: To determine the pCR rate after SABR and to assess oncologic and toxicity outcomes after a combined approach of neoadjuvant SABR followed by surgery. DESIGN, SETTING, AND PARTICIPANTS: A phase 2, single-arm trial, with patient accrual from September 30, 2014, to August 15, 2017 (median follow-up, 19 months), was performed at a tertiary academic cancer center. Patients 18 years or older with T1T2N0M0 NSCLC and good performance status, with adequate pulmonary reserve to undergo surgical resection, were studied. INTERVENTIONS: Patients underwent neoadjuvant SABR using a risk-adapted fractionation scheme followed by surgery 10 weeks later. MAIN OUTCOMES AND MEASURES: The pCR rate as determined by hematoxylin-eosin staining. RESULTS: Forty patients (mean [SD] age, 68 [8] years; 23 [58%] female) were enrolled. Thirty-five patients underwent surgery and were evaluable for the primary end point. The pCR rate was 60% (95% CI, 44%-76%). The 30- and 90-day postoperative mortality rates were both 0%. Grade 3 or 4 toxic effects occurred in 7 patients (18%). In patients receiving surgery, 2-year overall survival was 77% (95% CI, 48%-91%), local control was 100% (95% CI, not defined), regional control was 53% (95% CI, 22%-76%), and distant control was 76% (95% CI, 45%-91%). Quality of life did not decline after treatment, with no significant changes in mean Functional Assessment of Cancer Therapy for Lung-Trial Outcome Index score during the first year of follow-up. CONCLUSIONS AND RELEVANCE: The pCR rate after SABR for early-stage NSCLC was 60%, lower than hypothesized. The combined approach had toxic effects comparable to series of surgery alone, and there was no perioperative mortality. Further studies are needed to evaluate this combined approach compared with surgical resection alone. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02136355.
引用
- Palma DA, Nguyen TK, Louie AV, et al. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019. PMID: 30789648. doi:10.1001/jamaoncol.2018.6993
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。